Clinical Trial Update: Use of Direct-acting Antiviral to Treat HCV Recurrence After Liver Transplantation (ANRSCO23CUPILT) Infection

View source ↗

Summary

A clinical trial update on using direct-acting antiviral therapy to treat hepatitis C recurrence after liver transplantation (ANRS CO23 CUPILT).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Direct-acting antiviral agents

Snippet

Sponsor: ANRS, Emerging Infectious Diseases | Conditions: HCV Recurrence, Liver Transplantation | Status: UNKNOWN